The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
p53-Mediated Hematopoietic Stem and Progenitor Cell Competition
Open accessAbstract
Cell competition was originally described in Drosophila as a process for selection of the fittest cells. It is likely to play an important role in tissue homeostasis in all metazoans, but little is known about its role and regulation in mammals. By using genetic mosaic mouse models and bone marrow chimeras, we describe here a form of cell competition that selects for the least damaged cells. This competition is controlled by p53 but is distinct from the classical p53-mediated DNA damage response: it persists for months, is specific to the hematopoietic stem and progenitor cells, and depends on the relative rather than absolute level of p53 in competing cells. The competition appears to be mediated by a non-cell-autonomous induction of growth arrest and senescence-related gene expression in outcompeted cells with higher p53 activity. p53-mediated cell competition of this type could potentially contribute to the clonal expansion of incipient cancer cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Tp53 is also involved in cell competition regulation in both hematopoietic and non-hemopoietic tissues (Bondar & Medzhitov, 2010, Zhang, Xie et al., 2017).”
From Pu.1/Spi1 dosage controls the turnover and maintenance of microglia in zebrafish and mammals (2023) · cites this paper as Bondar & Medzhitov, 2010
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“we further showed that the chronic elimination of pu.1 -deficent microglia in zebrafish is mediated by Tp53-dependent cell competition”
From Pu.1/Spi1 dosage controls the turnover and maintenance of microglia in zebrafish and mammals (2023) · cites this paper as Bondar & Medzhitov, 2010
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Tp53 is also involved in cell competition regulation in both hematopoietic and non-hemopoietic tissues (Bondar and Medzhitov, 2010; Zhang et al., 2017).”
From Pu.1/Spi1 dosage controls the turnover and maintenance of microglia in zebrafish and mammals (2025) · cites this paper as Bondar and Medzhitov, 2010
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“which has been shown to depend on the relative level of Tp53 in competing cells (Bondar & Medzhitov, 2010, Zhang et al., 2017).”
From Pu.1/Spi1 dosage controls the turnover and maintenance of microglia in zebrafish and mammals (2023) · cites this paper as Bondar & Medzhitov, 2010
The cited source says what the claim attributes to it.
In the citing paper
“which has been shown to depend on the relative level of Tp53 in competing cells (Bondar and Medzhitov, 2010; Zhang et al., 2017).”
From Pu.1/Spi1 dosage controls the turnover and maintenance of microglia in zebrafish and mammals (2025) · cites this paper as Bondar and Medzhitov, 2010
In the citing paper
“and p53 upregulation in the haematopoietic system engenders myeloablation82,83”
From MDM2, MDMX and p53 in oncogenesis and cancer therapy (2013) · cites this paper as [82]
In the citing paper
“HSCs from mice with mutations in both Tp53 42 and Ppm1d, a gene encoding a regulator of p53 and other members of the DNA damage response pathway, 43,44 are able to enter cell cycle despite the presence of DNA damage, leading to a stem cell advantage in the setting of cytotoxic drugs.”
From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [42]
In the citing paper
“The desired cohort size was determined based on observations from previously reported experiments20”
From Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia (2015) · cites this paper as [20]
In the citing paper
“Importantly, a prior study similarly showed that Tp53+/− HSCs also have a competitive advantage following irradiation, which appeared to be due, at least in part, to reduced irradiation-induced senescence in Tp53+/− HSCs 20,21.”
From Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia (2015) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Blinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163
Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus
Srinivas, S., Watanabe, T., Lin, C.-S., William, C. M., Tanabe, Y., Jessell, T. M., & Costantini, F. (2001) · BMC Developmental Biology · doi:10.1186/1471-213x-1-4 · Cited by 3,121
Social controls on cell survival and cell death
RAFF, M. C. (1992) · Nature · doi:10.1038/356397a0 · Cited by 2,591
The first 30 years of p53: growing ever more complex.
Levine, A. J., & Oren, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2723 · Cited by 1,967
Clonal selection and learning in the antibody system
Rajewsky, K. (1996) · Nature · doi:10.1038/381751a0 · Cited by 1,701
Inducible Gene Targeting in Mice
Kühn, R., Schwenk, F., Aguet, M., & Rajewsky, K. (1995) · Science · doi:10.1126/science.7660125 · Cited by 1,641
The Age Distribution of Cancer and a Multi-stage Theory of Carcinogenesis
Armitage, P., & Doll, R. (1954) · British Journal of Cancer · doi:10.1038/bjc.1954.1 · Cited by 1,549
Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53
de Oca Luna, R. M., Wagner, D. S., & Lozano, G. (1995) · Nature · doi:10.1038/378203a0 · Cited by 1,420
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome
Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308
The age distribution of cancer and a multi-stage theory of carcinogenesis
Armitage, P., & Doll, R. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602297 · Cited by 1,292
Cited by
Sorted by citations
Programmed Cell Death in Animal Development and Disease
Fuchs, Y., & Steller, H. (2011) · Cell · doi:10.1016/j.cell.2011.10.033 · Cited by 1,915
Kastenhuber, E. R., & Lowe, S. W. (2017) · Cell · doi:10.1016/j.cell.2017.08.028 · Cited by 1,906
MDM2, MDMX and p53 in oncogenesis and cancer therapy
Wade, M., Li, Y.-C., & Wahl, G. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3430 · Cited by 1,279
Clonal hematopoiesis in human aging and disease
Jaiswal, S., & Ebert, B. L. (2019) · Science · doi:10.1126/science.aan4673 · Cited by 1,156
“HSCs from mice with mutations in either Tp53 (43) or Ppm1d, a gene encoding a regulator of p53 and other members of the DNA damage response pathway (44, 45), can enter the cell cycle despite the presence of DNA damage, leading to a stem cell advantage in the setting of cytotoxic drugs.”
P53 in survival, death and metabolic health: a lifeguard with a licence to kill.
Kruiswijk, F., Labuschagne, C. F., & Vousden, K. H. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm4007 · Cited by 1,080
Metadata
- Authors
- Bondar, T., & Medzhitov, R.
- Affiliations
- Howard Hughes Medical Institute (US)
- Corresponding author
- Medzhitov, Ruslan
- Venue
- Cell Stem Cell
- Publisher
- Elsevier BV
- Published
- 2010-04
- Volume
- 6
- Issue
- 4
- Pages
- 309-322
- ISSN
- 1875-9777 (ISSN-L)
- 1934-5909
- PMC
- PMC2872065
- OpenAlex
- W2163067447
- Cited by
- 342
- References
- 83
- Citations by year
- 2026: 15 · 2025: 17 · 2024: 14 · 2023: 23 · 2022: 22 · 2021: 25 · 2020: 29 · 2019: 22 · 2018: 18 · 2017: 21 · 2016: 24 · 2015: 25 · 2014: 23 · 2013: 20 · 2012: 12
- FWCI
- 10.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 1203 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- Cell stem cell (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institute of Allergy and Infectious Diseases (R01AI055502, R01AI046688)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK071754, P30DK072442)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Keywords
- cell competition, p53, hematopoietic stem cells, hematopoietic progenitor cells, clonal selection, DNA damage response, cellular senescence, growth arrest, bone marrow chimeras, genetic mosaicism, tissue homeostasis
- MeSH terms
- Animals, Cell Communication, Clone Cells, DNA Damage, Genes, Dominant, Hematopoietic Stem Cells, Models, Biological, Mutation, Phenotype, Radiation, Ionizing, Stress, Physiological, Tumor Suppressor Protein p53, Cellular Senescence, Apoptosis, Gene Expression Regulation, Developmental, Gene Expression Profiling, Cell Proliferation, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
